labiotech1h
Vicebio and its molecular clamp vaccine raise big to tackle respiratory viruses
Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...
ENDPOINTS NEWS3h
UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na
The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...
Too Old to Operate10h
Intervention of inflammation associated with ankylosing spondylitis by triptolide promotes histone H3 Iys-27 trimethylation.
Peripheral blood mononuclear cells (PBMCs) collected from 10 patients with active AS patients were exposed to TP, GSK-J4 or vehicle. T lymphocyte subsets were analyzed using flow cytometry. ELISA was ...
Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
The Pharma Letter23h
The week in pharma: action, reaction and insight – week to September 2024
Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...